spp allocation, page-10

I agree with you, dwalker, the only thing that annoys me is how they describe what they are going to do with these $15m, i.e. "generate value creating activities or exploring external activities"... meaning that they don't seem to have a plan or even a clue of what to do with it.

ACL (another biotech) is just going through the same process, and what they will do with the cash they will raise has been outlined on a very specific way. With ACL, we know how our money is going to be used, and it is reassuring to see that they know what they are doing.

I don't have this feeling with AVX. I think they have given us very little to justify this additional cr, especially after telling us, a few months before it was announced, they would be fine for a while.